{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:39:12Z","timestamp":1740173952349,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40744-023-00548-y","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T10:01:47Z","timestamp":1683367307000},"page":"849-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effie","family":"Pournara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumik","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"issue":"1","key":"548_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"10","key":"548_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"548_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40744-018-0115-5","volume":"5","author":"A Marchesoni","year":"2018","unstructured":"Marchesoni A. Oligoarticular psoriatic arthritis: addressing clinical challenges in an intriguing phenotype. Rheumatol Ther. 2018;5(2):311\u20136.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"548_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3899\/jrheum.210434","volume":"48","author":"DD Gladman","year":"2021","unstructured":"Gladman DD, Ye JY, Chandran V, Lee KA, Cook RJ. Oligoarticular vs polyarticular psoriatic arthritis: a longitudinal study showing similar characteristics. J Rheumatol. 2021;48(12):1824\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"548_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin N Am"},{"unstructured":"Cividino A, Nicholson D, Guindi S, Jelley J, Gaudreau AJ, Gladman D. Clinical presentation and treatment of oligoarticular psoriatic arthritis in Canada: high frequency of smaller joint involvement [abstract]. Arthritis Rheumatol 2019;71(Suppl 10).","key":"548_CR6"},{"issue":"1","key":"548_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-017-1424-8","volume":"19","author":"LJJ van Mens","year":"2017","unstructured":"van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP. Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther. 2017;19(1):226.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"548_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"548_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3899\/jrheum.150614","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016;43(2):356\u201361.","journal-title":"J Rheumatol"},{"issue":"8","key":"548_CR10","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368\u201377.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"548_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase\u00a03 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"2","key":"548_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393.","journal-title":"Br J Dermatol"},{"issue":"6","key":"548_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"14","key":"548_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"26","key":"548_CR15","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"548_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase\u00a0III study. Arthritis Rheumatol. 2021;73(1):110\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"548_CR17","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase\u00a03 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993\u20132003.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"548_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.","journal-title":"Arthritis Res Ther"},{"issue":"S3","key":"548_CR19","first-page":"364","volume":"24","author":"A Kivitz","year":"2018","unstructured":"Kivitz A, Nash P, Tahir H, et al. Arthritis: primary results through 52 weeks from a phase-3 randomized placebo-controlled study (FUTURE 4) [abstract]. J Clin Rheumatol. 2018;24(S3):364.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"548_CR20","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase\u00a0III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"doi-asserted-by":"crossref","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase\u00a03 MAXIMISE trial. Ann Rheum Dis. 2021;80:582\u201390.","key":"548_CR21","DOI":"10.1136\/annrheumdis-2020-218808"},{"issue":"1","key":"548_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase\u00a03 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23(1):190.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"548_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41687-019-0115-4","volume":"3","author":"D Cella","year":"2019","unstructured":"Cella D, Wilson H, Shalhoub H, et al. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019;3(1):30.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"548_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3899\/jrheum.170449","volume":"45","author":"L Gossec","year":"2018","unstructured":"Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol. 2018;45(1):6\u201313.","journal-title":"J Rheumatol"},{"issue":"11","key":"548_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215960","volume":"79","author":"RSG Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves RSG, de Almeida Martins LM, de Ataide MH, Dantas AT, Duarte ALBP. DAPSA versus cDAPSA: do we need to use CRP? Ann Rheum Dis. 2020;79(11):e142.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"548_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40744-021-00420-x","volume":"9","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Tillett W, Booth N, et al. Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe. Rheumatol Ther. 2022;9(1):285\u201393.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"548_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","volume":"77","author":"LJJ van Mens","year":"2018","unstructured":"van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis. 2018;77(2):251\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"548_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s13063-019-3627-6","volume":"20","author":"T Wilkinson","year":"2019","unstructured":"Wilkinson T, Sinha S, Peek N, Geifman N. Clinical trial data reuse\u2014overcoming complexities in trial design and data sharing. Trials. 2019;20(1):513.","journal-title":"Trials"},{"issue":"2","key":"548_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s13142-016-0386-8","volume":"6","author":"SI Bangdiwala","year":"2016","unstructured":"Bangdiwala SI, Bhargava A, O\u2019Connor DP, et al. Statistical methodologies to pool across multiple intervention studies. Transl Behav Med. 2016;6(2):228\u201335.","journal-title":"Transl Behav Med"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00548-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00548-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00548-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T17:01:40Z","timestamp":1688662900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00548-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00548-y","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}